Immuthera is a U.S.-based, wholly-owned subsidiary of Poland's PolTREG S.A., established to advance Tregulatory cell therapies in the American market. Its core asset is a licensed, first-in-class CD6/CTLA-4 CAR-Treg platform initially developed at City of Hope, with prior clinical evaluation in chronic refractory GvHD. The company aims to build a broad pipeline for autoimmune diseases by leveraging its parent company's clinical experience and pursuing partnerships for next-generation technologies, including mRNA/LNP-based in vivo Treg generation.
CoRe-T platform: First-in-class CD6/CTLA-4 CAR-Tregs (Counter Regulatory T-cells) designed to target and suppress autoreactive T-cells. Future plans include next-gen CAR-Tregs and in-vivo generated antigen-specific Tregs using mRNA/LNP technology.
Funding History
2
Total raised:$3.7M
Grant$1.2MPolish National Centre for Research and Development
Seed$2.5MUndisclosed
Opportunities
The global autoimmune disease market is vast and underserved, particularly for disease-modifying therapies in neuroinflammatory conditions like ALS and PPMS.
Success with its lead CD6/CTLA-4 CAR-Treg could validate the platform for rapid expansion into multiple high-value indications.
The strategic link to PolTREG provides clinical expertise and manufacturing, while the U.S.
subsidiary structure is ideal for attracting partnerships and navigating the lucrative American market.
Risk Factors
The company faces significant clinical risks associated with the novel and unproven mechanism of CAR-Tregs in autoimmune settings.
As a subsidiary, it is highly dependent on the financial and operational performance of its parent company, PolTREG.
The ambitious, broad pipeline may strain resources, and the company must successfully navigate the complex U.S.
regulatory pathway for a first-in-class cell therapy.
Competitive Landscape
Competition is intense from large biopharma companies developing biologic therapies (e.g., anti-IL, JAK inhibitors) and a growing number of biotechs exploring regulatory cell therapies, TCR-based therapies, and gene editing for autoimmunity. Immuthera's differentiation lies in its specific CD6/CTLA-4 targeting strategy and its access to prior clinical data from City of Hope.
